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Abstract
Background It is unclear which factors explain the
high co-morbidity between functional dyspepsia (FD)
and other functional somatic syndromes. The aim of
this study is to investigate the association between
gastric sensorimotor function, psychosocial factors
and ‘somatization’ on the one hand, and co-morbid
irritable bowel syndrome (IBS) and chronic fatigue
(CF)-like symptoms on the other, in FD. Methods In
259 tertiary care FD patients, we studied gastric sen-
sorimotor function with barostat (sensitivity, accom-
modation). We measured psychosocial factors (abuse
history, alexithymia, trait anxiety, depression, panic
disorder) and ‘somatization’ using self-report ques-
tionnaires, and presence of IBS and CF-like symptoms.
Hierarchical multiple logistic regression was used to
determine which of these factors were independently
associated with co-morbid IBS and CF-like symptoms,
including testing of potential mediator effects. Key
Results Co-morbid IBS or CF-like symptoms respec-
tively were found in 142 (56.8%) and 102 (39.4%)
patients; both co-morbidities were not signifi-
cantly associated (P = 0.27). Gastric accommodation
(b = 0.003, P = 0.04) and ‘somatization’ (b = 0.17, P =
0.0003) were independent risk factors for IBS (c = 0.74,
P < 0.0001); the effect of adult abuse (b = 0.72, P = 0.20)
was mediated by ‘somatization’. Depression (b = 0.16,
P = 0.008) and ‘somatization’ (b = 0.18, P = 0.004) were
overlapping risk factors for CF-like symptoms (c = 0.83,
P < 0.0001); the effects of alexithymia and lifetime
abuse were mediated by depression and ‘somatization’,
respectively. Conclusions & Inferences ‘Somatization’
is a common risk factor for co-morbid IBS and
CF-like symptoms in FD and mediates the effect of
abuse. Gastric sensorimotor function and depression
are specific risk factors for co-morbid IBS and CF-like
symptoms, respectively.
Keywords functional somatic syndromes, gastric
sensorimotor function, psychiatric disorders,
somatization.
Abbreviations: CF(S), chronic fatigue (syndrome); DIF,
difficulty identifying feelings & distinguishing between
feelings and bodily sensations; DSM-IV, Diagnostic and
Statistical Manual of Mental Disorders, 4th edition; DSS,
dyspepsia symptom score; FD, functional dyspepsia; FGID,
functional gastrointestinal disorders; FM, fibromyalgia;
FSS, functional somatic syndromes; GI, gastrointestinal;
IBS, irritable bowel syndrome; MDP, minimal distending
pressure; PHQ, Patient Health Questionnaire; STAI, State-
Trait Anxiety Inventory; TAS, Toronto Alexithymia Scale.
INTRODUCTION
Functional dyspepsia (FD) is one of the most prevalent
functional gastrointestinal disorders (FGID).1 Its etio-
pathogenesis remains incompletely understood and is
likely to be heterogeneous and multifactorial.1 Accord-
ing to the ‘biopsychosocial model’, FGID and other
‘functional somatic syndromes’ (FSS) result from a
complex and reciprocal interaction between biological,
psychological and social factors.2,3
Co-morbidity between FSS is high, with rates up to
50% and higher.3–10 Moreover, co-morbidity is associ-
ated with increased severity, greater impairment in
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quality of life, excess healthcare use including referrals
to secondary and tertiary care, and high direct and
indirect healthcare costs.11–15 Furthermore, co-morbid-
ity is not only high within the FGID group [e.g. between
FD and irritable bowel syndrome (IBS)]4,5,8,13,16,17 but
also between FGID and other FSS [e.g. fibromyalgia (FM)
and chronic fatigue syndrome (CFS)] (although specific
data on FD are rather sparse).3,6,10,12,13,18 Finally, there
is high co-morbidity with psychiatric disorders (espe-
cially mood and anxiety disorders) and a significant
association with psychosocial factors (including history
of sexual or physical abuse, ‘trait’/personality factors,
etc.) in all FSS.2,19–21
It remains highly unclear how this co-morbidity
should be explained. First, co-morbidity may simply be
an artifact caused by overlapping symptom criteria
and/or medical subspecialization.6,12,22,23 Second, it
may result from some common etiopathogenetic fac-
tor(s) that may be primarily peripheral and/or central in
origin.24 Potential peripheral mechanisms include a
‘panintestinal’ sensorimotor disorder of the gastroin-
testinal (GI) tract (for the overlap within the FGID
group) and/or primary immunological abnormalities,
whether or not triggered by an acute (GI) infection.5,12
Important examples of putative central mechanisms
are mainly psychobiological in nature. Psychiatric
disorders (e.g. depression) and a history of abuse
interfere with pain-processing systems in the
brain.25,26 ‘Somatization’, descriptively defined as a
tendency to experience and report multiple somatic
symptoms that cannot be adequately explained by
organic findings, seems to play an important role in
FSS co-morbidity.3,12,13,27–29 It remains a matter of
debate whether ‘somatization’ needs to be conceptual-
ized as a primary phenomenon (‘functional somatiza-
tion’) or rather as the result of a complex
psychobiological process in which psychological fac-
tors/processes such as abuse history, hypervigilance,
symptom-specific anxiety or negative affect lead to
amplification of bodily signals through central sensiti-
zation of interoceptive/pain-processing neural systems
(secondary phenomenon, ‘presenting somatiza-
tion’).19,24,28,30,31 Although the presently used mea-
sures conceptualize ‘somatization’ in a purely
descriptive way (i.e. by simply counting ‘unexplained’
somatic symptoms, corresponding at best with ‘func-
tional somatization’), evidence for the ‘presenting
somatization’ hypothesis is growing generally30,31 and
also more specifically applied to FGID.13,32
The potential explanations for FSS co-morbidity
described in the paragraph above are not mutually
exclusive and indeed likely to interact in a com-
plex way. Moreover, their relative contribution may
vary in these heterogeneous symptom-based dis-
orders. More specifically, several of the putative
central and peripheral mechanisms are likely to
reciprocally influence each other through the ‘brain-
gut axis’.24 So far, none of these explanations has
been found to explain co-morbidity to the full
extent.12,13,18,21,23
Given the paucity of co-morbidity research in FD,
the general aim of this study was to investigate the role
of gastric sensorimotor function, psychosocial factors/
psychiatric co-morbidity and ‘somatization’ as risk
factors for co-morbid IBS and chronic fatigue (CF)-like
symptoms in FD. More specifically, we aimed to test
the following hypotheses, based on the literature in
other FSS. The model underlying these hypotheses is
that FSS co-morbidity may result from a temporal and
potentially causal chain from childhood events to
symptom reporting in adulthood (from sexual/physical
abuse over stable psychological traits and vulnerability
for psychiatric co-morbidity to ‘somatization’). First,
‘somatization’ is a common risk factor for both
co-morbid IBS and CF-like symptoms in FD.12,18,33
Second, ‘somatization’ is a ‘mediator’ of the effect of
psychosocial factors (especially abuse history) on
co-morbidity.12,19,32,34 Third, depression is a more
important risk factor for CF-like symptoms than IBS
co-morbidity.18,21,35 Fourth, gastric sensorimotor dys-
function is a risk factor for IBS, but not for CF-like
symptom co-morbidity.5
METHODS
Patient sample
Consecutive Dutch-speaking patients recently diagnosed with FD
(either at their visit to our clinic or at a recent secondary care
gastroenterologist visit that led to referral to our center) were
recruited between January 2002 and February 2009. The patient
sample of the present study does partially overlap with two recent
studies from our group.36,37 However, the hypotheses tested in the
present study are novel and have not been reported elsewhere.
Further details about patient selection have been published
before.36
Gastric sensorimotor function testing
Details about gastric sensorimotor function testing have been
published before.36 Briefly, we used our standard barostat
protocol. During isobaric stepwise distension, patients scored
their perception of upper abdominal sensation at the end of every
distending step using a graphic rating scale (0–6) with verbal
descriptors. Discomfort threshold was defined as the lowest
pressure above minimal distending pressure evoking a perception
score of 5 or more. Meal-induced gastric relaxation (accommo-
dation) was quantified as the difference between the
average volumes during 30 min before and 60 min after meal
administration.
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Abuse history
A sexual and physical abuse questionnaire, developed and
validated in a GI population, was filled out on the day of the
study together with the questionnaires described below. This
questionnaire yields dichotomous answers for sexual and physical
abuse during childhood and adulthood.38
‘Trait’ psychological factors
Alexithymia Alexithymia is a stable psychological trait consist-
ing of three dimensions: difficulty identifying feelings & distin-
guishing between feelings and bodily sensations (DIF), difficulty
describing feelings and externally oriented thinking.39,40 As par-
ticularly the DIF dimension may play an important role in FSS,
including FGID,29,39,41 the DIF subscale of the well-validated
20-item Toronto Alexithymia Scale (TAS-20) was used through-
out the present study, yielding continuous scores.40
Trait anxiety The 20-item trait scale of the State-Trait Anxiety
Inventory (STAI) measures stable individual differences in ‘anxi-
ety proneness’, that is, ‘differences between people in the ten-
dency to perceive situations as threatening and to respond to them
with elevations in state anxiety’42 and yields a continuous total
score.
‘State’ psychiatric disorders
Depression The depression module of the Patient Health Ques-
tionnaire (PHQ-9) was used to screen for depressive co-morbidity
according to the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV).43 The nine DSM-IV depressive symptoms
(past 2 weeks) are rated on Likert scales (0–3). Depression score
(sum of the nine items) was used as a continuous variable.
Panic disorder The panic disorder module of the PHQ was com-
pleted, allowing a diagnosis of current DSM-IV panic disorder in a
dichotomous (yes/no) way.44
Somatic symptom reporting
‘Somatization’ The PHQ somatoform disorder module (PHQ-15)
is a well-validated self-report questionnaire composed of 15
somatic symptoms, including 14 of the 15 most prevalent DSM-IV
somatization disorder criteria.45 All items are rated on Likert
scales (0–2). Current ‘somatization’ (past month) was measured.
To avoid overlap with the depression measure (PHQ-9), which
may be problematic in the multiple regression models, and with
the fatigue outcome measure, we did not take into account the
two PHQ-15 items that are also included in the PHQ-9 depression
module (sleep, fatigue). Thus, the ‘somatization’ score we used
throughout the study is the sum of the remaining 13 items (‘PHQ-
13’). It should be noted that this abbreviated version is not a
validated instrument, which should be considered a limitation;
however, using the full PHQ-15 score yields similar results.
Moreover, a limitation of the PHQ-15 as a self-report measure
(without interview) is that it cannot distinguish between ‘med-
ically explained’ and ‘unexplained’ symptoms,45 which is an
important feature of the somatization concept.27,28 In this study,
adequate clinical and technical investigations were performed to
rule out a medical explanation of GI symptoms and other
potentially relevant symptoms, and major non-GI medical
co-morbidity that may account for these somatic symptoms was
ruled out on an ‘as needed’ basis. On the other hand, no
systematic investigation of all somatic symptoms included in
the PHQ-15 was conducted, as this is hardly practically feasible.
Thus, the PHQ symptom count in this study can only be
characterized as indicative of ‘(functional) somatization’. How-
ever, total self-reported PHQ somatic symptom counts are highly
associated with physician-rated somatoform disorder symptom
counts.45,46 Furthermore, the distinction between medically
explained and unexplained symptoms may be problematic and
less relevant than previously thought.14,47–49
Dyspepsia symptom severity (DSS) On the day of the study, the
intensity of nine dyspeptic symptoms was scored on Likert scales
[0–3 (absent, mild, moderate, severe)], as previously reported.
Dyspepsia symptom severity is defined as the sum of all nine
items.50
Weight loss Weight loss since the onset of dyspepsia symptoms
was determined by self-report at the inclusion outpatient clinic
visit (i.e. patients were weighed and were asked about the amount
of weight loss since the onset of their dyspepsia symptoms).
Co-morbid IBS and CF measurements
IBS Irritable bowel syndrome was assessed with a previously used
10-item yes/no self-report questionnaire, yielding a categorical
outcome (IBS diagnosis according to Rome II criteria).51
CF-like symptoms Chronic fatigue-like symptoms were consid-
ered present when the answers on two previously used yes/no
screening questions regarding duration (>6 months) of and dis-
ability due to fatigue were both positive.51
Statistical analysis
SAS 9.2 (SAS Institute, Cary, NC, USA) was used. If one or more
variables were missing for a patient, this patient was excluded
from all analyses in which the missing variable(s) was (were) used.
Data were presented as mean ± SD. Significance level was set at
P = 0.05 (two-tailed). One-way ANOVA and chi-square test for
contingency tables were used to compare groups according to
co-morbidity (none, IBS alone, CF-like symptoms alone, or both
co-morbidities).
Bivariate associations between gastric sensorimotor variables,
abuse history, ‘trait’ and ‘state’ psychological variables and
‘somatic symptom reporting’ variables on the one hand and
presence of co-morbid IBS or CF-like symptoms on the other were
calculated using simple logistic regression models.
Two multiple logistic regression models were built with the
presence of co-morbid IBS and CF-like symptoms as the dependent
variables. Gastric sensorimotor variables, abuse history, ‘trait’ and
‘state’ psychosocial variables and ‘somatic symptom reporting’
variables that were bivariately associated with the dependent
variable (P < 0.05) were entered into the regression model as
independent variables in a hierarchical way. Gastric sensorimotor
variables were entered in the first step, abuse history variables in
the second step, ‘trait’ psychological variables in the third step,
‘state’ psychiatric co-morbidity in the fourth step and ‘somatic
symptom reporting’ variables in the final step. Although it
remains to a certain extent speculative given the cross-sectional
nature of the present data, this order was chosen because it
reflects the putative temporal order of events leading to
co-morbidity best. For example, sexual/physical abuse has been
shown to be a risk factor for ‘trait’ psychological factors, ‘state’
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psychiatric co-morbidity and ‘somatization’ in longitudinal stud-
ies,19,32,52–54 ‘trait’ psychological factors are a risk factor for ‘state’
psychiatric co-morbidity,55 which has been demonstrated to be a
risk factor rather than a consequence of functional somatic
symptoms.56,57 Moreover, entering variables in this order (espe-
cially ‘somatization’ in the last step) can give an indication about
the putative mediational effects formulated in the hypothesis.
Although it should be noted that in principle, it is not theoret-
ically possible to study mediation in a cross-sectional sample
because it assumes temporal precedence (see definition below in
this paragraph). Therefore, the term mediation as used throughout
this article should be interpreted in a more limited sense, i.e.
devoid of its temporal precedence aspect. However, we decided to
use the term mediation as the order in which variables were
entered may well reflect the putative temporal order of events
based on the literature (see above).
When potential mediation was detected in the hierarchical
regression model, the mediation hypothesis was further tested as
described by Baron and Kenny, including the Sobel test for
significance of the indirect effect.58 We will use the classification
of risk factors formulated by Kraemer et al. throughout this
article.59
RESULTS
Patient characteristics
Three hundred thirty FD patients were asked to
participate. There were four refusals to participate
(1.2% of the total sample). Forty-six patients (13.9%)
canceled their study visit or didnot show up, allowing
280 barostat investigations to be performed. In 21
patients (6.4%), the procedure had to be stopped
prematurely as patients didnot tolerate tube insertion
or had severe discomfort once the tube was inserted.
Two hundred fifty-nine patients (78.5%) completed the
study. One hundred ninety-five patients (75.3% of the
completers) were women; the mean age was
39.5 ± 12.9 years.
Prevalence of co-morbidity and comparison
between co-morbidity groups
One hundred forty-two (56.8%) and 102 (39.4%)
patients had co-morbid IBS or CF-like symptoms,
respectively. Sixty-one patients (23.5%) had both
co-morbidities. Despite this overlap, IBS and CF-like
symptom co-morbidity were not significantly associ-
ated [v2(1) = 1.19, P = 0.27].
Table 1 shows the differences between four groups
based on co-morbidity: no co-morbidity (n = 70), co-
morbid IBS only (n = 80), co-morbid CF-like symptoms
only (n = 40) and both co-morbidities (n = 61). Patients
with co-morbid CF-like symptoms only and, to a lesser
extent, with co-morbid IBS-symptoms only and both
co-morbidities, differed significantly from the patients
with no co-morbidity. Most differences between the
co-morbidity groups were not significant.
Table 1 Comparison between FD patients with and without co-morbid IBS and/or chronic fatigue-like symptoms
Functional somatic symptom co-morbidity
P-value
None
(n = 70)
IBS only
(n = 80)
CF-like symptoms
only (n = 40)
IBS and CF-like
symptoms (n = 61)
Gastric sensorimotor function
Discomfort threshold 11.3 ± 4.0 9.4 ± 3.3* 9.4 ± 3.5* 9.4 ± 3.5* 0.005
Accommodation 97.4 ± 136.2 122.7 ± 133.2 79.4 ± 117.5 157.9 ± 143.8 0.02
Abuse history (%)
Childhood abuse 10 20.7 33.3 25 0.04
Adulthood abuse 3.7 17.2 16.7 22.7 0.01
Lifetime abuse 11.8 29.8 38.7 37.2 0.004§
‘Trait’ psychological
Trait anxiety 38.0 ± 10.8 40.5 ± 11.4 44.3 ± 11.6* 43.1 ± 12.4 0.03
Alexithymia – DIF 15.5 ± 6.0 16.4 ± 6.1 17.7 ± 6.6 17.4 ± 6.5 0.25
‘State’ psychological/psychiatric
Depression 6.2 ± 4.1 7.9 ± 5.7 11.5 ± 5.5*^ 9.6 ± 4.4* <0.0001§
Panic disorder (%) 7.25 15 25 18 0.05
Somatic symptom reporting
‘Somatization’ 7.7 ± 3.2 10.8 ± 3.7* 10.3 ± 4.8* 13.2 ± 4.3*^ <0.0001§
Dyspepsia symptoms 12.0 ± 5.2 13.8 ± 4.1 14.5 ± 4.4* 14.0 ± 4.9 0.03
Weight loss 5.9 ± 6.2 8.6 ± 7.6 12.0 ± 10.4* 10.9 ± 8.5* 0.001§
Significances in italic.
IBS, irritable bowel syndrome; CF, chronic fatigue; DIF, difficulty identifying and describing feelings.
P-value from one-way ANOVA with post hoc tests and Tukey adjustment for multiple comparisons (*significantly different from ‘none’; significantly
different from ‘CF-like symptoms only’; ^significantly different from ‘IBS only’).
P-value from chi-square test for 2 · 4 contingency tables.
§Remains significant after Bonferroni correction for multiple testing.
Volume 23, Number 6, June 2011 IBS and chronic fatigue in functional dyspepsia
 2011 Blackwell Publishing Ltd 527
Bivariate associations
Co-morbid IBS was associated with gastric sensorimo-
tor function (discomfort threshold, accommodation),
abuse history (adulthood sexual/physical abuse) and
‘somatization’, but not with ‘trait’ psychological fac-
tors or ‘state’ psychiatric co-morbidity (Table 2). The
association with ‘somatization’ remains significant
after Bonferroni correction for multiple testing. No
association with gender was found [v2(1) = 0.05,
P = 0.82].
Co-morbid CF-like symptoms were not associated
with gastric sensorimotor function, but with abuse
history (lifetime sexual/physical abuse), ‘trait’ psycho-
logical factors (trait anxiety and alexithymia), ‘state’
psychiatric co-morbidity (depression, panic disorder)
and ‘somatization’, DSS and weight loss. The associ-
ations with depression, ‘somatization’ and weight loss
remain significant after Bonferroni correction for
multiple testing. No association with gender was
found [v2(1) = 1.95, P = 0.16].
Multiple logistic regression
Gastric accommodation (P = 0.04) and ‘somatization’
(P = 0.0003) were significant risk factors for co-morbid
IBS in the final model (Table 3). This model was highly
significant (P < 0.0001), with concordance index
(c) = 0.74. The concordance index is a measure of the
predictive ability/discriminative power of a model and
represents the percent of all possible pairs of cases in
which the model assigns a higher probability to a
correct case than to an incorrect case; it gives an
estimate of the area under the receiver operating
characteristic (ROC) curve. As gastric accommodation
and ‘somatization’ are not correlated (r = 0.06,
Table 2 Bivariate associations of IBS and
chronic fatigue-like symptom co-morbidity with
GI sensorimotor, psychosocial and somatic
symptom variables (from simple logistic
regression)
Variable b ± SE OR (95% CI) P
Irritable bowel syndrome (positive cases n = 142)
Gastric sensorimotor function
Discomfort threshold )0.09 ± 0.04 0.92 (0.86–0.99) 0.02
Accommodation 0.003 ± 0.001 1.003 (1.001–1.004) 0.01
Abuse history
Childhood abuse* )0.23 ± 0.38 0.80 (0.38–1.66) 0.55
Adulthood abuse* )0.99 ± 0.47 0.37 (0.15–0.93) 0.03
Lifetime abuse* )0.56 ± 0.34 0.57 (0.29–1.12) 0.10
‘Trait’ psychological
Trait anxiety 0.01 ± 0.01 1.01 (0.99–1.03) 0.35
Alexithymia – DIF 0.01 ± 0.02 1.01 (0.97–1.06) 0.57
‘State’ psychological/psychiatric
Depression 0.02 ± 0.02 1.02 (0.97–1.07) 0.53
Panic disorder 0.17 ± 0.36 1.19 (0.59–2.40) 0.64
Somatic symptom reporting
‘Somatization’ 0.20 ± 0.04 1.22 (1.13–1.31) <0.0001
Dyspepsia symptoms 0.04 ± 0.03 1.04 (0.99–1.10) 0.12
Weight loss 0.02 ± 0.02 1.02 (0.99–1.06) 0.23
Chronic fatigue-like symptoms (positive cases n = 102)
Gastric sensorimotor function
Discomfort threshold )0.06 ± 0.04 0.94 (0.88–1.01) 0.10
Accommodation 0.001 ± 0.001 1.001 (0.999–1.003) 0.45
Abuse history
Childhood abuse* )0.67 ± 0.37 0.51 (0.25–1.05) 0.07
Adulthood abuse* )0.74 ± 0.42 0.48 (0.21–1.08) 0.08
Lifetime abuse* )0.73 ± 0.33 0.48 (0.25–0.92) 0.03
‘Trait’ psychological
Trait anxiety 0.03 ± 0.01 1.03 (1.01–1.06) 0.008
Alexithymia – DIF 0.04 ± 0.02 1.04 (1–1.09) 0.05
‘State’ psychological/psychiatric
Depression 0.13 ± 0.03 1.14 (1.08–1.20) <0.0001
Panic disorder 0.78 ± 0.35 2.17 (1.09–4.33) 0.03
Somatic symptom reporting
‘Somatization’ 0.16 ± 0.03 1.17 (1.10–1.25) <0.0001
Dyspepsia symptoms 0.06 ± 0.03 1.06 (1.00–1.12) 0.04
Weight loss 0.08 ± 0.02 1.08 (1.04–1.13) 0.0002
Significances in italic.
OR, odds ratio; DIF, difficulty identifying and describing feelings.
*Reference category = abuse; reference category = no panic disorder.
Remains significant after Bonferroni correction for multiple testing.
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P = 0.32), they can be considered independent risk
factors for IBS co-morbidity.59 Adult sexual/physical
abuse history was a significant risk factor for IBS
co-morbidity before ‘somatization’ was entered into
the model, which may be indicative of mediation of the
effect of abuse by ‘somatization’. Further formal test-
ing confirmed this mediational hypothesis (Fig. 1).
Significance of the indirect effect was confirmed using
the Sobel test (Z = )2.63, P = 0.008).
Significant risk factors for co-morbid CF-like symp-
toms in the final model were depression (P = 0.008),
‘somatization’ (P = 0.004) and weight loss (P = 0.05)
(Table 4). Given the fact that all these variables are
mutually correlated (0.21 < r < 0.36, all P < 0.002),
they should be considered overlapping risk factors for
co-morbid CF-like symptoms.59 The model was highly
significant (P < 0.0001, c = 0.83). Furthermore, the
effect of alexithymia – DIF was ‘mediated’ by depres-
sion (Fig. 2A). Significance of the indirect effect was
confirmed using the Sobel test (Z = 3.95, P < 0.0001).
The effect of lifetime overall abuse history was ‘med-
iated’ by ‘somatization’ (Fig. 2B); significance of this
indirect effect was borderline (Sobel test Z = )1.90,
P = 0.057).
DISCUSSION
To the best of our knowledge, this is the first study in
FD to investigate an extensive set of potential risk
factors for co-morbid IBS and CF-like symptoms,
including gastric sensorimotor function, psychosocial
factors/psychiatric co-morbidity and ‘somatization’.
Prevalence of co-morbidity
Fifty-seven percent of our FD patients had co-morbid
IBS. This is in line with previous research, although
most studies have reported somewhat lower figures (in
the 20–50% range), even in tertiary care.4,5,7,8,16 The
higher prevalence of co-morbid IBS in tertiary care is in
line with the finding that IBS is a predictor of referral in
primary care FD.11 Reported prevalences of the reverse
co-morbidity pattern (i.e. co-morbid FD in patients
presenting primarily with IBS) are generally even
higher, with figures up to 80% and more in tertiary
care,7–9 although considerably lower rates are reported
as well.13
Co-morbid CF-like symptoms were present in 40%
of the present FD sample. This is a novel finding, as
data on fatigue symptoms and co-morbidity with
chronic fatigue syndrome in FD are lacking. Data in
IBS are sparse as well, but generally lower than in the
present study (around 20% of co-morbid CF in IBS
samples); this may be due to the lack of data in tertiary
care.9,13 However, about 50% of CFS patients are
reported to have co-morbid IBS.9
Of our FD patients, 23.5% had both co-morbid IBS
and CF-like symptoms. This figure is in line with
previous studies on multiple co-morbidities in IBS.12,13
Both co-morbidities were not significantly associated
and most patient characteristics in the overlap group
were not different from both groups with only one
Table 3 Hierarchical multiple logistic
regression model with IBS co-morbidity as the
dependent variable (positive cases n = 142)
Variable b ± SEvariable OR (95% CI) pvariable cmodel
Step 1: Gastric sensorimotor function
Discomfort threshold )0.08 ± 0.04 0.93 (0.86–0.99) 0.04 0.63
Accommodation 0.002 ± 0.001 1.002 (1.00–1.004) 0.03
Step 2: Abuse history
Discomfort threshold )0.08 ± 0.05 0.92 (0.84–1.01) 0.09 0.66
Accommodation 0.002 ± 0.001 1.002 (1.00–1.004) 0.07
Adult abuse* )1.04 ± 0.51 0.35 (0.13–0.97) 0.04
Step 3: Somatic symptom reporting
Discomfort threshold )0.04 ± 0.05 0.96 (0.88–1.06) 0.46 0.74
Accommodation 0.003 ± 0.001 1.003 (1.00–1.005) 0.04
Adult abuse* )0.72 ± 0.55 0.49 (0.17–1.45) 0.20
‘Somatization’ 0.17 ± 0.05 1.18 (1.08–1.29) 0.0003
Significances in italic.
Probability modeled = presence of co-morbid IBS; all models P < 0.01.
*Reference category = abuse.
Adult abuse history
Adult abuse history
‘Somatization’
IBS
IBS
b = –0.62 ± 0.50°
b = –2.93 ± 0.86**
b = –0.99 ± 0.47*
b = 0.17 ± 0.04***
Figure 1 The effect of adult abuse history on co-morbid IBS
is mediated by ‘somatization’. *P < 0.05; **P < 0.01; ***P < 0.001;
P = 0.22; Sobel test Z = )2.63, P = 0.008.
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co-morbidity. Therefore, we limited the risk factor
analyses to co-morbid IBS (yes/no) and co-morbid
CF-like symptoms (yes/no), ignoring overlap.
Hypothesis 1 & 2: ‘Somatization’ as a risk factor
for co-morbid IBS and CF-like symptoms
‘Somatization’ was an independent risk factor for IBS
co-morbidity, whereas it acted as an overlapping risk
factor (with depression and weight loss) for CF-like
symptom co-morbidity. This is in line with both
epidemiological and psychophysiological work in IBS,
indicating that a ‘psychological’ tendency to perceive
and report somatic symptoms in general may be an
important mechanism underlying FSS symptom for-
mation and co-morbidity without, however, com-
pletely explaining co-morbidity.12,13,60,61 Furthermore,
‘somatization’ mediated (in its limited sense defined in
the methods section) the effect of abuse history on both
co-morbidities. It is conceivable that some intermedi-
ate psycho(bio)logical processes underlie the link
between abuse and ‘somatization’, including attach-
ment, hypervigilance toward somatic symptoms, pain
coping mechanisms and others. These psychological
processes may drive maladaptive mechanisms at the
neurobiological level such as deficient endogenous
pain modulation.19,30,31,34 The fact that such mecha-
nisms, and potential important precipitating factors,
including infections,18,21 were not included in this
study may account for the fact that the models
reported here do not classify all cases correctly.
Hypothesis 3: Depression is a risk factor for
co-morbid CF-like symptoms, but not IBS
This hypothesis was confirmed; a more important role
for depression in CF(S) compared to IBS is in line with
previous findings.18,21,35 It has indeed been shown that
psychiatric co-morbidity may explain FSS co-morbidity
partially but not fully.12,13,20,62 In the present study, we
found that depression and ‘somatization’ were both
significant, though overlapping risk factors for CF-like
symptom co-morbidity. It is indeed known that
depression and ‘somatization’ frequently occur
together, without, however, being identical entities.
This may be due to various reasons, including the fact
that current symptom criteria for depression contain
somatic items and/or the fact that depression interferes
with autonomic nervous system activity or interocep-
tive/pain processing at the brain level.26–28 Further-
more, the finding that depression ‘mediates’ the effect
of alexithymia (DIF dimension) on co-morbid CF-like
symptoms is also in line with previous research.29,55
Hypothesis 4: Gastric sensorimotor function
is a risk factor for co-morbid IBS, but not
CF-like symptoms
Gastric sensorimotor function was not associated with
CF-like symptoms, even in bivariate analysis. Gastric
accommodation was a significant independent risk
factor for co-morbid IBS, providing some support for
the ‘panintestinal (sensori)motor disorder hypothesis’
Table 4 Hierarchical multiple logistic
regression model with chronic fatigue-like
symptoms as the dependent variable (positive
cases n = 102)
Variable b ± SEvariable OR (95% CI) pvariable cmodel
Step 1: Abuse history
Lifetime abuse* )0.73 ± 0.33 0.48 (0.25–0.92) 0.03 0.58
Step 2: ‘Trait’ psychological
Lifetime abuse* )0.90 ± 0.36 0.41 (0.20–0.82) 0.01 0.69
Trait anxiety 0.013 ± 0.017 1.01 (0.98–1.05) 0.45
Alexithymia – DIF 0.06 ± 0.03 1.07 (1.00–1.13) 0.04
Step 3: ‘State’ psychological/psychiatric
Lifetime abuse* )1.02 ± 0.38 0.36 (0.17–0.76) 0.007 0.75
Trait anxiety )0.01 ± 0.02 0.99 (0.95–1.03) 0.60
Alexithymia – DIF 0.03 ± 0.03 1.03 (0.97–1.10) 0.36
Depression 0.14 ± 0.04 1.16 (1.06–1.26) 0.001
Panic disorder 0.21 ± 0.51 1.24 (0.46–3.35) 0.67
Step 4: Somatic symptom reporting
Lifetime abuse* )0.71 ± 0.45 0.49 (0.20–1.19) 0.11 0.83
Trait anxiety 0.001 ± 0.02 1.00 (0.96–1.04) 0.95
Alexithymia – DIF 0.005 ± 0.04 1.01 (0.93–1.08) 0.90
Depression 0.16 ± 0.06 1.17 (1.04–1.31) 0.008
Panic disorder 0.84 ± 0.65 2.32 (0.64–8.35) 0.20
‘Somatization’ 0.18 ± 0.06 1.20 (1.06–1.35) 0.004
Dyspepsia symptoms )0.08 ± 0.05 0.92 (0.83–1.02) 0.11
Weight loss 0.06 ± 0.03 1.06 (1.00–1.12) 0.05
Significances in italic.
Probability modeled = presence of co-morbid CF; all models P < 0.05.
*Reference category = abuse; Reference category = no panic disorder.
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to explain co-morbidity within the FGID group. Gas-
tric sensitivity was a (borderline) significant risk factor
for co-morbid IBS before ‘somatization’ was entered
into the model. Gastric hypersensitivity as measured
here may be the manifestation of a more generalized
hypersensitivity for somatic stimuli. Such a general-
ized hypersensitivity may be a key physiological
mechanism in FSS in general and in one of the
psychobiological mechanisms underlying ‘somatiza-
tion’.10,30,31 We therefore may speculate that gastric
sensitivity and ‘somatization’ may act as proxy risk
factors for IBS co-morbidity, which is supported by
their significant correlation (r = )0.22, P = 0.0006); this
term does, contrary to ‘mediator’, not contain an
assumption on temporal precedence.59 In other words,
gastric hypersensitivity would be one aspect or man-
ifestation of the multidimensional process of ‘somati-
zation’. This is supported by evidence showing that
psychosocial factors may influence (gastric) sensory
thresholds.63
Limitations
First, we used self-report measures, which may be
prone to certain forms of bias. For example, abuse
history questionnaires may be prone to recall bias and
their results may be confounded by present depressive
symptoms.64 However, the abuse measures we used are
validated specifically in (functional) GI populations38
and have been widely used. Although a structured
clinical interview remains the ‘gold standard’ for
diagnosing psychiatric co-morbidity, we chose self-
report measures that have been validated with a
structured interview as a comparison. Furthermore,
some potentially relevant variables, including coping
strategies, were not evaluated in this study but should
be included in future research.
Second, this is a cross-sectional observational study,
permitting conclusions about associations but not
about causality, temporal order or directionality of
the relationships between the variables studied. For
example, the order in which (groups of) variables were
entered in the regression models was chosen to reflect
the putative temporal order of things in the best way
possible (based on conceptual and empirical grounds),
but this remains an assumption. Strictly speaking,
mediation requires temporal precedence of the medi-
ator by the mediated variable.59 However, we used the
term mediation in a more limited sense (i.e. devoid of
its temporal precedence aspect) throughout this paper.
Therefore, the results should be interpreted with
sufficient caution and require replication in longitudi-
nal studies before any definite conclusions can be
drawn.
Third, the patient population consists of tertiary care
FD patients, limiting generalizability of the results
toward other populations of FD patients.
Fourth, the CF measurement was based on two non-
validated screening questions; it should therefore be
regarded as indicative of co-morbid CF-like symptoms,
not as a full assessment of chronic fatigue syndrome
according to its diagnostic criteria.
CONCLUSION
First, ‘somatization’ is a common risk factor for
co-morbid IBS and CF-like symptoms in FD. Second,
‘somatization’ is a ‘mediator’ of the effect of abuse
history on co-morbid IBS and CF-like symptoms.
Third, co-morbid depression is a risk factor for CF-like
symptoms, but not IBS co-morbidity; it ‘mediates’ the
effect of alexithymia (DIF dimension). Fourth, gastric
sensorimotor dysfunction is a risk factor for IBS, but
not CF-like symptom co-morbidity. These findings add
to the existing evidence on co-morbidity with other
FSS in FD, which is likely to be the result of a complex
interplay between biological, psychological and social
factors. More specifically, different FSS seem to share
certain etiopathogenetic mechanisms [especially
(abuse-induced) ‘somatization’] without, however,
being completely overlapping and/or identical, which
is in line with previous research in FSS.9,12,13,23
A
B
b = 0.04 ± 0.02*
b = 0.14 ± 0.03***
b = –0.73 ± 0.33*
b = –1.48 ± 0.70*
b = 0.37 ± 0.05***
b = 0.19 ± 0.04***‘Somatization’
Depression
Alexithymia-DIF
Alexithymia-DIF
Lifetime abuse
history
Lifetime abuse
history
CF
CF
CF
CF
b = –0.01 ± 0.03°
b = –0.62 ± 0.36°
Figure 2 (A) The effect of alexithymia – DIF on co-morbid CF is
mediated by depression. *P < 0.05; ***P < 0.001; P = 0.57; Sobel test
Z = 3.95, P < 0.0001. (B) The effect of lifetime abuse history on
co-morbid CF is mediated by ‘somatization’. *P < 0.05; ***P < 0.001;
P = 0.09; Sobel test Z = )1.90, P = 0.057.
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In other words, the truth may lie somewhere in
between completely ‘lumping’ or ‘splitting’ these dis-
orders but it remains to be elucidated which of these
two extreme positions comes closest to reality. Further
research is especially needed to elucidate the psycho-
biological mechanisms that may underlie what we
now descriptively call ‘somatization’.
The clinical message emerging from this study may
lie in the importance of screening for co-morbid
‘intestinal’ and ‘extra-intestinal’ FSS in patients pre-
senting primarily with FD symptoms. This approach
may identify a subgroup of patients that may benefit
most from interventions, whether pharmacological or
psychotherapeutical, that target psychiatric co-morbid-
ity and/or ‘somatization’ and its putative underlying
psychobiological mechanisms, rather than the organ
that corresponds to the primary symptoms with which
the patient is primarily presenting.65
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